Latest Leadership News

Critical Minerals Group names COO Pat Kelly as interim CEO following Scott Winter's resignation to lead BTP. The company confirms its strategy and Lindfield Vanadium Project plans remain steady during the transition.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Australian Foundation Investment Company (ASX:AFI) reported a $293.5 million profit for FY26, holding dividends steady despite portfolio returns lagging the market. Leadership transitioned as Alison Gibson took the helm following Mark Freeman’s retirement.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Shine Justice Ltd reported a modest 2.3% revenue increase to $209.2 million for FY26, alongside a striking 1,578% jump in net profit after tax to $9.6 million. The company declared a fully franked final dividend of 2.5 cents per share, signalling confidence amid ongoing investments in technology and international expansion.

Julian Cook has resigned as an executive director of Winton Land, citing fundamental disagreements with the majority shareholder on board roles and governance, following similar departures by other directors.